Description
Waklert (Armodafinil) 150 mg
Waklert 150 mg is presented as an oral tablet containing armodafinil, a wakefulness-promoting medicine. Armodafinil is the active R-enantiomer of modafinil and is used in established prescribing information for certain causes of excessive sleepiness.
Active Ingredient and Medicine Class
The verified active ingredient is armodafinil. It is a wakefulness-promoting agent and is classified as a central nervous system stimulant-like medicine, although its exact mechanism differs from classic amphetamine stimulants.
Established Medical Uses
In official prescribing information, armodafinil is indicated to improve wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. In obstructive sleep apnea, it is used for residual sleepiness and is not a substitute for treatment of the underlying airway obstruction.
How It Works
Armodafinil helps promote alertness by influencing brain systems involved in sleep and wake regulation. Its wake-promoting effect is thought to involve multiple neurotransmitter pathways, including effects on dopamine signaling, rather than acting through the same mechanism as traditional stimulants.
Important Safety Information
Armodafinil is contraindicated in people with known hypersensitivity to armodafinil, modafinil, or related ingredients. Official labeling warns about rare but serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, as well as drug reaction with eosinophilia and systemic symptoms. It should be used cautiously in people with cardiovascular disease, psychiatric history, liver impairment, or a history of rash with related medicines.
Important interactions include reduced effectiveness of hormonal contraceptives, possible reduced blood levels of cyclosporine, and altered exposure to some drugs metabolized by CYP3A4/5 or CYP2C19. Caution is also advised with warfarin and MAO inhibitors. Armodafinil is a controlled substance and has potential for misuse or dependence.
Possible Side Effects
Commonly reported adverse effects include headache, nausea, dizziness, insomnia, and anxiety. Some patients may experience palpitations, increased heart rate, or increased blood pressure. Serious reactions can include severe rash, allergic reactions, psychiatric symptoms such as agitation or hallucinations, and rare cardiovascular events.
Scientific Evidence
Clinical trials in adults have shown that armodafinil can improve measures of wakefulness and patient-reported alertness in narcolepsy, shift work disorder, and residual sleepiness in treated obstructive sleep apnea. Published reviews and randomized studies generally support short-term benefits on sleepiness outcomes, while also emphasizing the need to consider adverse effects and the underlying sleep disorder being treated.
Medical Information Notice
This summary is based on official prescribing information and selected peer-reviewed literature available at the time of review. It is for educational purposes only and does not replace the official patient leaflet or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed. Armodafinil Tablets, for oral use, C-IV: Full Prescribing Information. View official prescribing information
- Charles A. Czeisler et al. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Journal article indexed in PubMed, 2009. View scientific article
- Teofilo Lee-Chiong Jr. et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Journal article indexed in PubMed, 2006. View scientific article
